Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial Cystitis
- Conditions
- Painful bladder syndrome / interstitial cystitis (PBS/IC)MedDRA version: 1Level: LLTClassification code 10005063Term: <Manually entered code. Term in E.1.1>
- Registration Number
- EUCTR2008-001501-42-FI
- Lead Sponsor
- Jukka Sairanen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Tacrolimus calcineurin inhibition in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) treatment?
How does Tacrolimus compare to Elmiron (pentosan polysulfate sodium) in PBS/IC symptom management efficacy and safety?
Which urothelial integrity or inflammatory biomarkers predict response to Tacrolimus in EUCTR2008-001501-42-FI?
What are the nephrotoxicity and immunosuppressive toxicity risks of Tacrolimus in PBS/IC patients from EUCTR2008-001501-42-FI?
Are there synergistic combination therapies involving Tacrolimus and P2X3 antagonists for bladder pain syndrome?